Efficacy and Safety of Short-Course Radiotherapy Alone or Combined With Consolidation Chemotherapy Versus Conventional Long-Course Chemoradiotherapy for Locally Advanced Rectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

J Gastrointest CancerOct 28, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Chaoyang Wang, Yaguang Han, Shuxin Xue et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis of randomized controlled trials compared short-course radiotherapy (SCRT), with or without consolidation chemotherapy, against long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer. Nine trials involving 3,061 patients were included. Compared with standard LCCRT, SCRT-based total neoadjuvant therapy (TNT) increased pathological complete response (RR = 1.56, 95% CI: 1.24-1.97, P = 0.0002), but also increased grade ≥ 3 acute toxicity. Overall and disease-free survival did not differ significantly. SCRT alone had lower acute toxicity but poorer pathological response and downstaging than LCCRT.

Key findings

  • SCRT-based TNT increased pathological complete response versus standard LCCRT (RR = 1.56, 95% CI: 1.24-1.97, P = 0.0002).
  • Grade ≥ 3 acute toxicity was higher with SCRT-based TNT (RR = 1.63, 95% CI: 1.14-2.34, P = 0.008).
  • SCRT alone was associated with lower pathological complete response (RR = 0.13, 95% CI: 0.03-0.51, P = 0.003) and lower acute toxicity (RR = 0.12, 95% CI: 0.05-0.29, P < 0.00001) than LCCRT.
  • SCRT-based TNT showed no significant overall-survival difference (HR = 0.99, 95% CI: 0.76-1.28, P = 0.91) or disease-free-survival difference (HR = 1.05, 95% CI: 0.77-1.43, P = 0.77) versus standard LCCRT.

Why it matters

The findings distinguish SCRT-based TNT from SCRT alone rather than treating short-course regimens as interchangeable. Higher complete-response rates with SCRT-based TNT did not correspond to demonstrated survival benefit and came with more severe acute toxicity, while SCRT alone traded lower toxicity for weaker tumour response. These differences are relevant when weighing neoadjuvant treatment outcomes.

What to keep in mind

The comparison of SCRT-based TNT with LCCRT-based TNT was exploratory and based on a single small trial, leaving that comparison inconclusive.

Source

Published in J Gastrointest Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.